BioInformant

Your Global Leader in Stem Cell Market Research

Home » Exosomes » Page 2

Aegle Therapeutics Raises $4M to Fund First Trial in the U.S. Using Exosomes from Allogeneic MSCs

By

Aegle Therapeutics raises $4 million to fund a groundbreaking stem cell exosome clinical trial to treat the orphan disease, Dystrophic Epidermolysis Bullosa.

BOSTON and MIAMI, Jan. 7, 2020 — Aegle Therapeutics Corp., a first in class biotechnology company isolating extracellular vesicles, including exosomes (“EVs”), secreted by mesenchymal stem cells as therapy, announced the closing of a $4M financing. Aegle’s platform technology is initially being developed to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric skin blistering disorder.  [Read more…]

Market Forces Driving Growth of the Exosome Industry

By

Market forces driving growth of the exosome have been expanding over the past two years, with increasing investment flowing into the space, merger and acquisition (M&A) activity accelerating, and new therapeutics entering various stages of development. Exosomes are defined as small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. They are made in some form by all species, including bacteria that produce analogous outer membrane vesicles (OMC). [Read more…]

Current Snapshot of the Exosome Market – Who’s Who and Who’s Doing What?

By

To operate within the exosome market, it is vital to assess novel opportunities for product development. The most developed market segment involves research products that utilize stem cell exosomes, with these tools being sold to researchers in laboratories worldwide. However, exosomes can also be commercialized as therapeutic agents, diagnostic tools, and cosmeceuticals. Additionally, manufacturing technologies are being developed to support exosome production. [Read more…]

Stem Cell Medicine Manufacturing MSC-Derived Exosomes for Treatment of Autism

By

With autism spectrum disorder (ASD) affecting between 1-2% of the population and affecting all racial, ethnic, and socioeconomic groups, the condition is becoming of global importance. While the pharma industry has not yet been able to deliver a solution for this disease, the cell therapy industry is now undertaking the challenge. [Read more…]

NeurExo Sciences to Host Teach-in Featuring Michael Chopp, PhD and Pioneering Exosome Technology

By

— Research indicates exosomes have therapeutic potential for improving recovery after stroke, traumatic brain injury —

ATLANTA and DETROIT, January 23, 2019 – NeurExo Sciences, LLC (NXS), a biopharmaceutical company and subsidiary of NeuroTrauma Sciences, LLC, will be hosting a teach-in event featuring leading exosome researcher, Michael Chopp, Ph.D., Vice Chairman, Department of Neurology and Scientific Director, Neurosciences Institute, Zoltan J. Kovacs Chair of Neuroscience Research at Henry Ford Health System (HFHS), Detroit, and Distinguished Professor of Physics, Oakland University (MI).  Dr. Chopp’s presentation will provide a primer and overview of exosomes, small extracellular vesicles that provide a means of mediating intercellular communication.  He also will focus on his team’s pioneering technology employing exosomes engineered with enriched microRNA for the purpose of treating neurological disease and injury, including stroke and traumatic brain injury (TBI). [Read more…]

BioInformant's World-Class Clients